You can view 5 more pages without signing in

Prognosis

Last reviewed 1 Jan 2018

Individuals heterozygous for familial hypercholesterolaemia (FH) experience an increased risk of coronary heart disease and death from myocardial infarction (MI) in middle life.

if left untreated, men and women with heterozygous FH with total cholesterol levels of 8-15 mmol/L (310-580 mg/dL) typically develop CHD before age 55 and 60, respectively, while homozygotes with total cholesterol levels of 12-30 mmol/L (460-1160 mg/dL) typically develop CHD very early in life and if untreated die before age 20
however, once diagnosed, heterozygotes can readily be treated with cholesterol-lowering medication to attenuate development of atherosclerosis and to prevent CHD

Reference:

Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ . Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.